Thrombosis Research
Volume 121, Issue 6 , Pages 727-734, 2008

Protein Z levels and anti-protein Z antibodies in patients with arterial and venous thrombosis

  • José Pardos-Gea

      Affiliations

    • Department of Internal Medicine, Research Unit for Autoimmune Diseases, Spain
  • ,
  • José Ordi-Ros

      Affiliations

    • Department of Internal Medicine, Research Unit for Autoimmune Diseases, Spain
    • Corresponding Author InformationCorresponding author. Department of Internal Medicine, Vall d’Hebrón University Hospital, Paseo Vall d’Hebrón 119-129, 08035 Barcelona, Spain. Tel.: +34 93 274 61 67; fax: +34 93 489 40 45.
  • ,
  • Silvia Serrano

      Affiliations

    • Department of Internal Medicine, Research Unit for Autoimmune Diseases, Spain
  • ,
  • Eva Balada

      Affiliations

    • Department of Internal Medicine, Research Unit for Autoimmune Diseases, Spain
  • ,
  • Inmaculada Nicolau

      Affiliations

    • Department of Haematology, Haemostasis Unit, Vall d’Hebrón University Hospital, Universidad Autónoma de Barcelona, Barcelona, Spain
  • ,
  • Miquel Vilardell

      Affiliations

    • Department of Internal Medicine, Research Unit for Autoimmune Diseases, Spain

Received 28 February 2007; received in revised form 27 June 2007; accepted 5 July 2007.

Abstract 

Introduction

The thrombotic risk associated with protein Z (PZ) deficiency is unclear. Anti-protein Z (anti-PZ) has been described as a risk factor in unexplained embryo demise. The aim of our study was to evaluate a possible PZ deficiency and presence of anti-PZ antibodies on thrombotic diseases.

Material and methods

We performed a case-control study on 114 patients with preexisting arterial or venous thrombosis (50 and 64, respectively). Thrombosis was studied based on etiology (creating factor risk subgroups) and on specific thrombotic disease.

Results

PZ levels of patients were significantly lower compared to controls (1709+761.3 ng/mL vs. 2437+964.7 ng/mL P=0.001). The high arterial risk factor subgroup showed the lowest PZ level (1267.5+609 ng/mL) whereas the rest of arterial and venous etiological subgroups presented similar PZ levels. Patients with peripheral artery disease had the lowest PZ level (1022+966 ng/mL). The rest of arterial and venous thrombotic diseases presented similar PZ levels. A significant increased risk for arterial and venous thrombosis for the lowest (<1685 ng/mL) quartile of PZ has been founded (OR:52, P=0.001 and OR:18, P=0.007, respectively). Anti-PZ antibodies were negative in the majority of patients, although mean anti-PZ IgG antibody levels in the arterial thrombosis group were significantly higher compared to venous thrombosis and control groups (P=0.05 and P=0.005, respectively).

Conclusions

The results suggest that both arterial and venous thrombotic events are related to low PZ levels and that low PZ concentrations are associated with thrombosis in our study. In arterial thrombosis our findings strengthen previous studies that related low PZ levels to atherosclerotic disease. Anti-PZ antibodies do not seem to play a potent role in thrombosis.

Abbreviations:: PZ, protein Z, anti-PZ, anti-protein Z, ZPI, protein Z-dependent protease inhibitor, Xa, activated factor X, OD, optical density, AU, arbitrary unit, PBS, phosphate buffered saline, NCEP-III, National Cholesterol Education Program, ANOVA, analysis of variance, SD, standard deviation, OR, Odds ratios.

Keywords: Anti-Protein Z, Arterial thrombosis, Protein Z, Venous thrombosis, Protein Z deficiency, Thrombophilia

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Author’s contributions: José Pardos-Gea (designed research, performed research, collected data, analyzed data, wrote the paper); José Ordi-Ros (designed research, performed research, revised content); Silvia Serrano, Eva Balada, Inmaculada Nicolau (designed research, contributed vital new reagents and analytical tools); Miquel Vilardell (designed research, revised content).

PII: S0049-3848(07)00309-X

doi:10.1016/j.thromres.2007.07.009

Thrombosis Research
Volume 121, Issue 6 , Pages 727-734, 2008